title: N-(1-arylpropionyl)-4-aryltetrahydropyridines, a new class of high-affinity selective sigma receptor ligands.
abstract: A series of N-(1-arylpropionyl)-4-aryl-1,2,3,6-tetrahydropyridines, prepared by simple Mannich condensations, have been found by radioligand binding assays to have moderate to high affinity (IC50 0.5-500 nM) for bovine cerebellar sigma receptor/binding sites and no measurable affinity (IC50 > 5000 nM) for bovine striatal D2 receptors. The most active of these compounds rival in potency the most active sigma ligands previously reported. Three of these sigma-active compounds were screened for pharmacological activity under the NIMH-NovaScreen program and showed moderate affinity only for D2 and 5-HT2 receptors among the 40 sites assayed. Since these N-(1-arylpropionyl)-4-aryltetrahydropyridines are structurally related to other potent sigma receptor ligands, in particular haloperidol and 4-phenylpiperidines, these data provide insights into the nature of the essential pharmacophore of the sigma receptor. The selective affinity of these materials for sigma receptors indicates they have potential as prototypes of novel psychotherapeutic medicinal agents, particularly as antipsychotic drugs which would be devoid of debilitating side effects associated with blockade of D2 receptors.
authors.affiliation: Department of Chemistry, New York University, New York 10003.
authors.forename: D I
authors.initials: DI
authors.lastname: Schuster
authors.forename: Y P
authors.initials: YP
authors.lastname: Pan
authors.forename: G
authors.initials: G
authors.lastname: Singh
authors.forename: G
authors.initials: G
authors.lastname: Stoupakis
authors.forename: B
authors.initials: B
authors.lastname: Cai
authors.forename: G
authors.initials: G
authors.lastname: Lem
authors.forename: G K
authors.initials: GK
authors.lastname: Ehrlich
authors.forename: W
authors.initials: W
authors.lastname: Frietze
authors.forename: R B
authors.initials: RB
authors.lastname: Murphy
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000138:chemical synthesis* / Q000378:metabolism; D001665:Binding Sites; D001667:Binding, Competitive; D002417:Cattle; D002531:Cerebellum / Q000378:metabolism; D004095:Dihydropyridines / Q000138:chemical synthesis* / Q000378:metabolism; D006220:Haloperidol / Q000378:metabolism; D007650:Ketanserin / Q000494:pharmacology; D011427:Propiophenones / Q000138:chemical synthesis* / Q000378:metabolism; D011725:Pyridines / Q000138:chemical synthesis* / Q000378:metabolism; D011869:Radioligand Assay; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D017480:Receptors, sigma / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism / Q000494:pharmacology
chemical_list: D014150:Antipsychotic Agents; D004095:Dihydropyridines; D011427:Propiophenones; D011725:Pyridines; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D017480:Receptors, sigma; C084679:N-(1-phenylpropionyl)-4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine; C084680:N-(1-phenylpropionyl)-4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine; D013134:Spiperone; D007650:Ketanserin; D006220:Haloperidol